Mechanisms of differential regulation of interleukin-6 mRNA accumulation by tumor necrosis factor alpha and lymphotoxin during monocytic differentiation  by Brach, Marion A. et al.
Volume 263, number 2, 349-354 FEBS 08367 April 1990 
Mechanisms of differential regulation of interleukin-6 mRNA 
accumulation by tumor necrosis factor alpha and lymphotoxin during 
monocytic differentiation 
Mar ion  A. Brach*, Nicola A Cicco, Detlev Riedel, Toshio H i rano °, Tadamitsu Kishimoto °, Ro land H. 
Merte lsmann and Fr iedhelm Her rmann 
Department of lnternal Medicine L University of Freiburg, Freiburg, FRG and °Institute for Molecular and Cellular Biology, 
Osaka University, Osaka, Japan 
Received 5 February 1990; revised version received 5 March 1990 
In the present report we compare the capacity of two related cytokines, tumor necrosis factor (TNF) alpha and lymphotoxin (LT), to modulate 
mRNA levels of interleukin-6 (IL-6) in cells representing different stages of monocytic differentiation including the human leukemia cell lines HL 
60, U 937, THP-1, MonoMac l and peripheral blood monocytes. We show that the capacity of TNF alpha and LT to induce IL-6 mRNA accumula- 
tion increases as monocytic differentiation proceeds with TNF alpha being more potent than LT, suggesting that alternate pathways may be used 
by differentiating cells to control expression of IL-6. In contrast, in monocytes which constitutively synthesize IL-6 transcripts, TNF alpha and 
LT treatment had opposite ffects on levels of IL-6 mRNA accumulation. In these cells TNF alpha enhanced steady state levels of IL-6 transcripts 
due to mRNA stabilization, whereas LT shortened IL-6 mRNA half-life, most likely due to induction of a RNA destabilizer since LT-mediated 
downregulation f levels of IL-6 mRNA in monocytes could be prevented by inhibition of protein synthesis. Neither TNF alpha nor LT altered 
IL-6 mRNA accumulation by interfering with preexisting transcription factors ince both TNF alpha and LT required de novo protein synthesis 
to exert their effects. 
Gene expression; Interleukin-6; Tumor necrosis factor; Lymphotoxin 
1. INTRODUCTION 
Interleukin-6 (IL-6) is a multifunctional cytokine 
with numerous synonyms reflecting its distinct 
biological activities uch as B-cell stimulatory factor 2, 
interferon beta-2 and hybridoma/plasmacytoma 
growth factor [1]. IL-6 is known to play a central role 
in the immune response, in acute phase reactions and 
in hematopoiesis [1,2]. Dysregulation of IL-6 expres- 
sion is involved in the pathogenesis of various chronic 
inflammatory diseases, autoimmune states, and lym- 
pho/hematopoietic disorders [3]. The molecular clon- 
ing of the IL-6 gene has revealed a 5-kb gene consisting 
of 5 exons and four introns, containing three transcrip- 
tional initiation sites and three TATA-Iike sequences 
[4]. A c-fos serum response lement, a recognition site 
for signals mediated by cAMP and for binding of 
transcriptional enhancer el ments uch as AP-1 have 
been identified in the highly conserved 5' flanking 
region of the IL-6 gene. Two AU-rich islands have been 
detected in its 3' untranslated region [4]. These se- 
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quences largely contribute to the instability of the IL-6 
mRNA [5] and have also been identified in many other 
cytokine genes or proto-oncogenes whose expression is
transiently regulated by external stimuli [6]. Many dif- 
ferent cell types such as monocytes, fibroblasts, 
keratinocytes, endothelial cells, T-cells and B-cells syn- 
thesize IL-6 either constitutively or following induction 
by a variety of stimuli [1]. However, cells of the 
monocyte/macrophage lin age are believed to repre- 
sent the major physiologic source of IL-6 [7-9]. Signal 
transduction pathways controlling IL-6 gene expression 
involve activation of protein kinase C as well as cAMP 
[1]. A tissue specific preferential utilization of distinct 
initiation sites suggests distinct regulatory mechanisms 
controlling IL-6 gene expression i  different cell species 
[4,10,11]. Mechanisms that account for differential 
regulation of the IL-6 gene during ontogeny of a 
distinct cell type are, however, still unknown. In the 
present study we have analyzed the regulation of IL-6 
gene expression i  various monocytic ells belonging to 
different stages of monocytic differentiation i cluding 
the human leukemia lines HL 60, U937, THP-1, and 
MonoMac 1 and normal peripheral blood monocytes. 
As inducers of IL-6 expression in these cells two other 
cytokines have been instrumental because of their 
known stimulatory effects on IL-6 transcript synthesis 
in other cell species, namely tumor necrosis factor 
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(TNF)  a lpha  and  lymphotox in  (LT)  [12]. Compar i son  
o f  the  capac i ty  o f  these cytok ines  to induce  IL -6  expres-  
s ion  was o f  par t i cu la r  in terest  because  o f  the i r  known 
ab i l i ty  to exert  d i f fe rent ia l  ef fects  on  express ion  levels 
o f  o ther  genes desp i te  shar ing  the same receptor  
[12-14] .  
2. MATERIALS  AND METHODS 
2.1. Biological reagents and cDNAs 
Recombinant human (rh) tumor necrosis factor alpha (spec. act. 
5 × 10 7 U/mg of protein) and rh lymphotoxin (spec. act. 108 U/mg 
of protein) were kindly provided by G. Adolf, Boehringer, Vienna, 
Austria. The monoclonal ntibody anti-CD 14, kindly provided by J. 
Griffin, Dana Farber Cancer Institute, Boston, MA, was used to con- 
trol purity of monocyte preparations a d to assess the stage of 
monocytic differentiation of the respective leukemia cell line. The 
cDNA probe for IL-6 was produced by two of us (T.H. and T.K.) 
and was derived from a Taql/Banll fragment of pBSF 2.38; the beta- 
actin probe, a 2.2 PstI fragment of the pAl plasmid, was kindly pro- 
vided by J. Ramadori, 1. Medical Department, University of Mainz, 
FRG. 
respectively, following a 4-h incubation period in standard culture 
medium. 
2.5. Extraction of cellular RNA and Northern blot analys& 
Total cellular RNA was isolated as previously described [18,19] by 
lysing cells in guanidinium isothiocyanate followed by recovery of 
RNA by centrifugation through cesium chloride. RNA was subse- 
quently denatured by treatment with a buffer containing for- 
maldehyde/formamide/morpholinopropanolsulfonic acid (Serva, 
Heidelberg, FRG) at 65°C. Samples of 20 ,ag were fractionated on a 
1 °70 formaldehyde agarose gel and blotted onto synthetic membranes 
(Schleicher and Schuell, Dassel, FRG). Messenger RNA of interest 
was detected using an IL-6-specific probe. The probe was labelled by 
primer extension with [o~-32p]dCTP (3000 Ci/mmol). Membranes 
were prehybridized overnight at 42°C in a solution containing 1 M 
NaC1, 1070 SDS, 10°70 dextran sulfate, 100/zg/ml salmon sperm. 
Hybridization was performed in an identical solution supplemented 
with 1 x l0 s cpm/ml abelled probe. The membranes were washed in 
decreasing concentrations of SSC at 65°C, dried and exposed to 
Kodak X-Omat films with intensifying screen for 2-3 days. To ex- 
clude incomplete RNA transfer in single lanes, all membranes were 
reprobed for beta-actin. In selected experiments relative signal inten- 
sity of hybridization was determined by laser densitometry [12]. 
2.2. Cell lines 
All cell lines were grown in RPMI 1640 medium (Gibco, Grand 
Island, NY), supplemented with 10070 low endotoxin FCS (Hazelton 
Laboratories, Vienna, VA), 4 mM L-glutamine, 100 ng/ml strep- 
tomycin, 100 U/ml penicillin, and 10 mM sodium pyruvate (Gibco) 
(= standard culture medium) at a cell density of 10 6 cells/ml. In 
selected experiments culture medium was also supplemented with 
polymyxin B (10/zg/ml; Sigma, Munich, FRG) to prevent effects of 
possibly contaminating lipopolysaccharide. From each cell type, 50 x 
106 cells were exposed to either increasing concentrations of TNF 
alpha (101 , 102, 103 or 5 x 103U/ml) or LT (101 , 10 z, 103 or 
104 U/ml) for 4 h or to a maximum stimulating dose of TNF alpha 
(5 x 103 U/ml) or LT (104 U/ml) for 4, 8 and 12 h and then subjected 
to RNA analysis. HL 60, U 937 and THP-1 cells were purchased from 
the American Type Culture Collection, the MonoMac 1 line was 
kindly provided by H.W.L. Ziegler-Heitbrock, Institute for Im- 
munology, University of Munich, FRG [15]. 
2.3. Preparation of peripheral blood monocytes 
Peripheral blood-derived mononuclear cells (PBMC) were isolated 
from platelet phoresis bags obtained from Consenting healthy 
volunteer donors by Ficoll-Hypaque (Seromed, Berlin, FRG) density 
separation (specific density of 1.078 kg/l). A fraction enriched for 
monocytes was obtained by a second ensity separation (specific den- 
sity of 1.062 kg/1) of E-rosette-negative PBMCs as described 
elsewhere [16]. Individual cell fractions were assessed by morphology 
(Wright/Giemsa and alpha naphthyl acetate sterase staining) and 
immunofluorescence analysis employing monoclonal anti-CD 14 an- 
tibody [17]. This procedure reveals monocyte preparations of more 
than 95% purity. 
3. RESULTS 
3.1. Stage of  monocytic differentiation of  cells to be 
studied 
The CD 14 molecu le  is expressed on  the sur face  o f  
approx imate ly  90°7o o f  per iphera l  b lood  monocytes  and  
is p rogress ive ly  acqu i red  dur ing  monocyte  ontogeny .  
Tab le  I ind icates  sur face  express ion  f  CD 14 on  all cell 
species s tud ied  by  immunof luorescence  analys is  w i th  
ant i -CD 14 monoc lona l  ant ibody  and  demonst ra tes  a 
maturat ion  w i th  HL  60 cells be ing  more  immature  than  
U 937 > THP 1 > MonoMac 1 > b lood  monocytes .  
3.2. Constitutive IL-6 expression during monocytic 
differentiation 
In  cont ras t  to monocytes  wh ich  const i tu t ive ly  syn- 
thes ized  stab le  IL -6  t ranscr ip ts ,  IL -6 mRNA was 
undetectab le  in HL  60, U 937, THP-1  and  MonoMac 
1 cells (Figs 1A,B  and  2). 
3.3. TNF alpha-mediated regulation of  IL-6 gene 
expression during monocytic differentiation 
In  the  promye locyt i c  cell l ine HL  60, known to be in- 
duced  by  TNF  a lpha  to d i f fe rent ia te  a long  the 
2.4. Culture of monocytes 
Monocytes were plated in standard culture medium in plastic Petri 
dishes (Falcon, Oxnard, CA) at a density of 2 x 10 6 cells per ml for 
3-12 h with or without TNF alpha or LT. In selected experiments 
cycloheximide (CHX; Sigma, Munich, FRG) (10/~g/ml) was added 
either 45 min prior to incubation with TNF alpha or LT for 4 h or 
for a 3-h incubation period that was preceded by 3 h of culture in the 
presence or absence of TNF alpha or LT. In additional experiments 
monocytes were exposed to actinomycin D (Sigma, Munich, FRG) 
(5/~g/ml) for various periods of time (30, 60, 90 and 120 min) follow- 
ing a 4-h incubation period with or without TNF alpha or LT. In a 
third set of experiments, monocytes were incubated with actinornycin 
D (5/~g/ml) with or without cycloheximide (10 ,ug/ml) for 1 or 3 h, 
Table I 
CD 14 expression of cells studied 
Cell species Surface expression of CD 14 (%) 
HL 60 0 
U 937 5-8 a 
THP-1 24-26 
MonoMac 1 58-63 
Blood monocytes 89 96 
a Range of percent assessed by three different occasions 
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Fig. 1. (A) Time-dependent effect of TNF alpha and LT on levels of IL-6 mRNA in the cell lines HL 60, U 937, THP-I and MonoMac (MM) 
1). Cells were incubated in the presence or absence of TNF alpha (5 x IO3 U/ml) or LT (lo4 U/ml) for various periods of time. Cytoplasmic 
RNA (20 pg/lane) was hybridized with an IL-6specific cDNA (I 6 kb). Re~ybridization of the filters with beta-a~tin-specific cDNA confirmed 
identical RNA loading in single lanes (not shown). (B) Dose-dependent effect of TNF alpha and LT on levels of lL-6 mRNA in the cell lines 
HL 60, U937, THP-1 and MM 1. Cells were incubated in the presence or absence of various concentrations of TNF alpha and LT for 4 h. 
Cytoplasmic RNA (20 pg/Iane) was hybridized with an IL-f-specific cDNA (1.6 kb). Rehybridization of the filters with beta-actin-specific cDNA 
confirmed identical RNA loading in single lanes (not shown). 
monocytic pathway [20], TNF alpha failed to induce 
detectable IL-6 mRNA at all concentrations in- 
vestigated (Fig. 1B). In U937 cells only exposure to an 
otherwise maximum dose of TNF alpha (5 x lo3 U/ml) 
for 4 h resulted in detectable IL-4 mRNA levels 
(Fig. 1B) that declined within a further 4-8 h to 
baseline levels (Fig. IA). In the THP-1 cell line TNF 
alpha stimulated IL-6 mRNA accumulation already 
when given at a concentration of 10’ U/ml for 4 h, 
leading to a dose-dependent stronger signal when the 
TNF alpha dose was increased to 5 x IO3 U/ml 
(Fig. 1B). Again, after prolongation of the culture 
period IL-6 mRNA levels declined but were still detec- 
table (Fig. 1A). In the more mature monocytic cell line 
MonoMac I, IL-6 mRNA accumulation was induced in 
a dose-dependent fashion by all TNF alpha concentra- 
tions used (Fig. lB), with maximum hybridization 
signals detectable at 4 h of culture (Fig. 1A). In 
monocytes which constitutively expressed IL-6 mRNA, 
TNF alpha treatment resulted in an enhancement of 
IL-6 transcript levels at 4 h that declined back to star- 
ting levels when monocytes were exposed to TNF alpha 
for a further 4 h (Fig. 2). 
3.4. LT-mediated IL-6 regulation of IL-6 gene 
expression during monocyt~c differentiation 
Similar to TNF alpha, LT failed to induce IL-6 
mRNA accumulation in the promyelocytic HL 60 line, 
but failed also to induce IL-6 transcripts in U 937 cells 
(Fig. 1B). Low levels of IL-6 mRNA were stimulated in 
THP-1 cells by LT, as compared to IL-6 levels induced 
by TNF alpha. In the more mature MonoMac 1 cells, 
LT was even more potent in stimulating IL-6 expres- 
sion. In these cells IL-6 mRNA accumulated at all LT 
concentrations investigated after 4 h of culture 
(Fig. 1A). In contrast to all cell lines investigated, LT 
downregulated constitutively expressed IL-6 mRNA 
levels in monocytes after 4 h of culture (Fig. 2). 
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Fig. 2. Time-dependent effect of TNF alpha nd LT on levels of IL-6 
mRNA in peripheral blood monocytes. Freshly separated monocytes 
were either directly subjected to mRNA analysis (control) or were 
incubated in the presence or absence of TNF alpha (5 × 10 ~ U/ml) 
or LT (104 U/ml) for 4 and 12 h. Identical experiments were also 
performed with polymyxin B as culture supplement a d gave 
comparable results, thus ruling out possible influences of 
contaminating lipopolysaccharide. Cytoplasmic RNA (20/~g/lane) 
was hybridized with an1L-6-specific cDNA (1.6 kb). Rehybridization 
of the filters with beta-actin-specific cDNA confirmed identical RNA 
loading in single lanes (not shown). 
O 0.5 1 1.5 2 
Time ( h ) 
Fig. 3. Stability of 1L-6 mRNA levels in peripheral blood monocytes 
cultured with or without TNF alpha or LT. Monocytes were cultured 
in the presence or absence (closed squares) of TNF alpha (open 
squares) (5 × 103 U/ml) or LT (open circles) (104 U/ml) for 4 h and 
then actinomycin D (5/~g/ml) was added to the cultures for 0.5-2 h. 
Cytoplasmic RNA (20/zg/lane) was sequentially hybridized to IL-6 
and beta-actin-specific cDNA. Blots were analyzed by laser 
densitometry. Values are expressed as actual mRNA levels relative to 
baseline mRNA levels (= 100%). 
After a 12-h culture period in the presence or absence 
of LT (10 4 U/ml) ,  IL-6 mRNA levels were in- 
distinguishable r gardless of whether LT was present in 
the culture or not, suggesting that a short acting LT- 
induced mechanism ay have led to a decay of IL-6 
mRNA in these cells. 
3.5. Regulation mechanisms governing IL-6 mRNA 
accumulation in monocytes in response to 
TNF alpha or L T 
High levels of constitutively expressed IL-6 mRNA in 
monocytes declined to undetectable levels when 
monocytes were exposed to actinomycin D for 2 h 
(5/~g/ml), suggesting an IL-6 mRNA half-life of less 
than 1 h. In monocytes exposed to TNF alpha (5 x 
10 3 U/ml )  for 4 h prior to actinomycin D, however, 
Northern blot analysis still revealed abundant  IL-6 
message after xposure to act inomycin D for 2 h, sug- 
gesting a prolongation of the half-life of IL-6 mRNA 
by TNF  alpha. In contrast, a more rapid decay of ac- 
cumulated IL-6 mRNA occurred in LT (10 4 U/ml) -  
stimulated monocytes as compared to untreated con- 
trois (Fig. 3), thus suggesting an LT-mediated 
destabil ization f constitutively expressed IL-6 mRNA.  
Inhibit ion of protein synthesis by CHX (10/~g/ml) for 
3 h was followed by an increase of IL-6 message in 
uninduced and induced monocytes (Fig. 4), suggesting 
that de novo protein synthesis interferes with IL-6 
mRNA stability in each cell sample. Incubat ion with 
cycloheximide for 45 min that was followed by stimula- 
t ion with TNF alpha (5 x 103 U/ml )  or LT (104 U/ml)  
abolished TNF alpha- and LT-mediated IL-6 mRNA 
modulat ion (Fig. 4), suggesting that both LT and TNF 
alpha require de novo protein synthesis to exert their ef- 
fects. To show whether mRNA accumulation in 
monocytes is regulated by labile proteins, monocytes 
were exposed to act inomycin D either alone or in com- 
b inat ion with CHX. As shown in Fig. 5, CHX delayed 
decay of IL-6 mRNA.  When transcription of the IL-6 
gene was blocked by actinomycin D treatment for 1 h, 
levels of IL-6 mRNA declined to 50°70 of baseline. Pro- 
longation of the actinomycin D treatment o 3 h 
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Fig. 4. Effect of CHX treatment on levels of IL-6 mRNA in 
monocytes induced by TNF alpha (5 × 103 U/ml) and LT 
(104 U/ml). Monocytes were cultured in the presence of TNF alpha 
or LT for 4 h and then either CHX (10/zg/ml) or fresh medium was 
added to the culture for a further 3 h. In lane 1 the primary culture 
was with LT, the secondary culture with medium. Lane 2 shows the 
treatment sequence medium/medium; lane 3: TNF/medium; lane 6, 
LT/CHX; lane 7: medium/CHX; lane 8: TNF/CHX. In the 
experiments depicted in lanes 6 and 8, LT or TNF were not present 
during the incubation period with CHX. In other experiments the 
effects of CHX treatment that was followed by exposure of cells to 
either TNF or LT on steady-state l vels of IL-6 mRNA were 
investigated. The primary culture was performed with CHX for 
45 min followed by a 4-h culture with LT (lane 4) or TNF alpha (lane 
5). Cytoplasmic RNA (20 ,ug/ml) was sequentially hybridized to 1L-6 
and beta-actin-specific cDNA. 
I L -6  
1 2 :3 4 5 
Actin 
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Fig. 5. Effect of CHX treatment on the stability of IL-6 mRNA levels 
in peripheral blood monocytes. Monocytes were cultured in the 
presence of medium and then actinomycin D (act D; 5/zg/ml) was 
added to the cultures either alone or in combination with CHX 
(10/zg/ml) for 1 or 3 h. Lane 1: monocytes cultured in medium 
alone; lane 2:exposure to act D for 1 h; lane 4: exposure to act D for 
3 h. In lanes 3 and 5 act D was combined with CHX either for 1 (lane 
3) or 3 h (lane 5). Cytoplasmic RNA (30,ug/ml) wassequentially 
hybridized to 1L-6 and beta-actin-specific cDNA. 
resulted in complete decay of IL-6 mRNA.  However, 
when blockade of transcription was combined with in- 
hibit ion of protein synthesis by CHX,  IL-6 mRNA was 
still detectable. 
4. DISCUSSION 
Despite considerable structural identity of 36°7o and 
homology of 52°7o f the amino acid sequence [21] and 
funct ional  similarities [20,22] TNF alpha and LT are 
also known to differ in their capacity to induce certain 
cytokines [12-14]. Both polypeptides share a common 
receptor [23], although they probably interact in a dif- 
ferent fashion with this receptor [24]. Distinct receptor 
affinities have been accounted for the distinct 
biological capacities of both cytokines [23,24]. In the 
present paper we demonstrate hat the potential of LT 
to induce IL-6 message in the less-differentiated cell 
lines U937 and THP-1 is reduced as compared to the 
action of TNF alpha, although LT has been shown to 
shar  with TNF alpha the ability to spur differentiation 
of THP-1 cells [20,25]. In monocytes, however, both 
cytokines.display even opposite ffects on IL-6 mRNA 
accumulat ion,  which cannot simply be explained by 
different receptor binding alone. It is well known that 
posttranscript ional mechanisms govern accumulat ion 
of certain mRNAs such as mRNA of some proto- 
oncogenes [26] or growth factors [27]. Alternate 
pathways in growing and differentiating cells have 
recently been reported to selectively control c-myc 
mRNA accumulat ion [28]. It has been shown for in- 
stance that c-myc expression in plasma cells is under 
transcriptional control of short-lived repressor 
molecules which are, however, inactive in early B- 
lineage cells [29]. Therefore, the apparent rationale for 
regulating gene expression of a mult i funct ional  
biological molecule such as IL-6 in cells maturing along 
the monocytic line by distinct cytokines is to provide 
alternate transcriptional or posttranscriptional 
pathways as labile proteins acting as short-lived 
repressors/derepressors  interfering with mRNA 
stability. As presented here, neither cytokine modulates 
accumulat ion of the IL-6 mRNA by interacting with 
preexisting transcription factors (either repressors or 
activators) since both TNF alpha and LT require de 
novo protein synthesis to exert their effects. Induct ion 
of transcriptional ctivators uch as AP-1, which has 
recently been shown to mediate TNF alpha-induced 
collagenase gene expression in fibroblasts [30] or of G- 
binding proteins known to mediate effects of TNF 
alpha on endothelial cells [31], might also be involved 
in LT and TNF alpha-modulated IL-6 gene expression. 
In uninduced as in induced monocytes, IL-6 mRNA is 
under control of short-lived destabilizers leading to 
superinduct ion f IL-6 message as soon as protein syn- 
thesis is inhibited. Preexisting nucleases, which interact 
with the AU-r ich islands and thus cause rapid degrada- 
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tion of mRNA by random endonucleolytic cleavage, 
have been proposed to cause rapid turnover of the c-fos 
mRNA [32]. A similar mechanism could account for 
regulation of IL-6 mRNA.  However, apart from that, 
LT also induces a destabilizer or a short-lived 
repressor, leading to shortening of the IL-6 half-life 
and downregulat ion f the IL-6 message as compared 
to untreated controls. Since ongoing transcription does 
not necessarily correlate with mRNA accumulat ion 
[26,27], LT-induced downregulation might well be due 
to a LT- induced destabilizer rather than an inhibit ion 
of IL-6 gene transcription. On the other hand, a dif- 
ferent expression pattern of labile proteins in response 
to LT may account for the increase of IL-6 mRNA 
mediated by LT in less mature MonoMac 1 cells. The 
recent observation that TNF alpha-stimulated IL-6 ex- 
pression is downregulated in THP-1 cells when protein 
synthesis is inhibited [33] but upregulated in 
monocytes, as shown here, also suggests alternate post- 
transcriptional pathways mediated by cytokine-induced 
short-lived proteins which then selectively regulate IL-6 
gene expression along the monocytic pathway. So far, 
mechanisms leading to shut-off of induced transcrip- 
t ion of genes are poorly understood. Nuclear factors 
such as AP-1, however, may possibly become active on- 
ly transiently after cellular induction through specific 
modif ications uch as phosphorylat ion or allosteric 
changes [34]. Studies are now under way to further 
determine to which extent either transcriptional or 
posttranscriptional mechanisms account for TNF 
alpha- and LT-modulated IL-6 gene expression in 
monocytes and whether nuclear transcription factors 
such as the c-jun/AP-1 complex or G-proteins are in- 
volved. 
Acknowledgements': The authors would like to thank Drs H.W.L. 
Ziegler-Heitbrock for donation of the MonoMac 1 cell line and J. 
Griffin for the kind gift of the anti-CD 14 antibody. This study was 
supported by Deutsche Forschungsgemeinschaft He 1380-2/1 and 
BMFT 0319012B. 
REFERENCES 
[1] Hirano, T. and Kishimoto, T. (1990) in: Peptide Growth 
Factors and Their Receptors (Sporn, M.B. and Roberts, A.B. 
eds) Springer, Berlin, in press. 
[2] Clark, S.C. (1989) Ann. NY Acad. Sci. 557, 438-443. 
[3] Hirano, T. (1990) in: Hematopoietic Growth Factors in Clinical 
Applications (Mertelsmann, R. and Herrmann, F. eds) Marcel 
Dekker, New York, in press. 
[4] Yarukawa, K., Hirano, T., Watanabe, Y., Muratani, K., 
Matsuda, T. and Kishimoto, T. (1987) EMBO J. 6, 2939-2945. 
[5] Shaw, G. and Kamen, R. (1986) Cell 46, 659-665. 
[6] Caput, D., Beutler, B., Hartog, K., Thayer, R., Brown- 
Shirmer, S. and Cerami, A. (1986) Proc. Natl. Acad. Sci. USA 
83, 1670-1676. 
[7] Aarden, L.A., De Groot, E.R., Schaap, O.L. and Landsdorp, 
P.M. (1987) Eur. J. lmmunol. 17, 1411-1417. 
[8] Bauer, J., Ganter, U., Geiger, T., Jacobshagen, U., Hirano, 
T., Matsuda, T., Kishimoto, T., Andus, T., Acs, G., Gerok, 
W. and Ciliberto, G. (1988) Blood 72, 1134-1140. 
[9] Navarro, S., Debili, N., Bernaudin, J.F., Vainchenker, W. and 
Boly, J. (1989) J. Immunol. 142, 4339-4345. 
[10] Weissenbach, J., Chernajovsky, Y., Zeevi, M., Schulman, L., 
Soreq, H., Nir, U., Wallach, D., Perricandet, M., Tiollais, P. 
and Revel, M. (1980) Proc. Natl. Acad. Sci. USA 77, 
7152-7157. 
[11] Walther, Z., May, L.T. and Sehgal, P.B. (1988) J. lmmunol. 
140, 974-980. 
[12] Mantovani, L., Henschler, R., Brach, M.A., Wieser, R., 
L/ibbert, M., Lindemann, A. Mertelsmann, A.R.H. and 
Herrmann, F. (1990) Eur. J. Biochem., in press. 
(13] Oster, W., Lindemann, A., Horn, S., Mertelsmann, R. and 
Herrmann, F. (1987) Blood 70, 1700. 
[14] Locksley, R.M., Heinzel, F.P., Shepard, H.M., Agosti, J., 
Eessalu, T.E., Aggarwal, B.B. and Harlan, J.M. (1987) J. 
Immunol. 139, 1891-1897. 
[15] Ziegler-Heitbrock, H.W.L., Thiel, E., F/itterer, A., Herzog, 
V., Wirtz, A. and Riethmtiller, G. (1988) Int. J. Cancer 41,
456-461. 
[16] Recalde, H.R. (1984) J. Immunol. Methods 69, 71-75. 
[17] Herrmann, F., Cannistra, S.A., Levine, H. and Griffin, J.D. 
(1985) J. Exp. Med. 265, 1111 116. 
[18] Maniatis, T., Fritsch, E.F. and Sambrook, J. (1982) Molecular 
Cloning: A Laboratory Manual, Cold Spring Harbor 
Laboratory, Cold Spring Harbor, NY. 
[19] Herrmann, F., Cannistra, S.A., Lindemann, A., Blohm, D., 
Rambaldi, A., Mertelsmann, R. and Griffin, J.D. (1989) J. 
lmmunol. 142, 139-145. 
[20] Trinchieri, G., Kobayashi, M., Rosen, M., London, R., 
Murphy, M. and Perussia, B. (1986) J. Exp. Med. 164, 
1206-1214. 
[21] Pennica, D., Nedwind, G.E., Hayflick, J.S., Seehung, P.H., 
Berynck, R., Palladino, M.A., Kohr, W.J., Aggarwal, B.B. 
and Goeddel, D.V. (1984) Nature 312, 724-727. 
[22] Broxmeyer, H.E., Williams, D.E., Lu, I., Cooper, S., 
Anderson, S.L., Beyer, G.S., Hoffmann, R. a d Rubin, B.Y. 
(1986) J. Immunol. 136, 4487-4493. 
[23] Aggarwal, B.B., Eessalu, T.E. and Hass, P.E. (1985) Nature 
318, 665-669. 
[24] Strauber, G. and Aggarwal, B.B. (1989) J. Biol. Chem. 139, 
1891-1897. 
[25] Hemmi, H., Nakamura, T., Tamura, K., Shimizu, Y., Kato, 
S., Miki, T., Takabashi, N., Muramatsu, M., Numara, N. nd
Sugamura, K. (1987) J. lmmunol. 138, 664-669. 
[26] Sariban, E., Luebbers, R. and Kufe, D. (1988) Mol. Cell Biol. 
8, 340 346. 
[27] Horiguchi, J., Sariban, E. and Kufe, D. (1988) Mol. Cell Biol. 
8, 3951-3954. 
[28] Swarthout, S.G. and Kinnisburgh, A.J. (1989) Mol. Cell Biol. 
9, 288-295. 
[29] Kakkis, E., Riggs, K.J., Gillespie, W. and Alame, K. (1989) 
Nature 339, 718-720. 
[30] Brenner, D.A., O'Hara, M., Angel, D., Chojker, M. and 
Karin, M. (1989) Nature 337, 661-664. 
[31] Brett, J., Gerlach, H., Nawroth, D., Steinberg, S., Godman, 
G. and Stern, D.C. (1989) J. Exp. Med. 169, 1977-1983. 
[32] Wilson, T. and Treismann, R. (1988) Nature 336, 396-399. 
[33] Sanceau, J., Beranger, F., Gaudelet, C. and Wietzerbin, J. 
(1989) Ann. NY Acad. Sci. 557, 130-143. 
[34] Gonzalez, G.A., Yamamoto, K.K., Fischer, W.H. Karr, D., 
Minzel, P., Biggs, W. III, Vale, W.W. and Montminiy, M.R. 
(1989) Nature 337, 749-753. 
354 
